Category: District of Delaware
-
Moderna appeals to save $1.3 billion patent dispute payout, asserts U.S. government-contractor immunity
Moderna has alleged that a district courtâs conclusions in a case against Arbutus are âdeeply flawedâ and that the U.S. Congress created Section 1498 specifically to shield government contractors from liability for government-authorized patent use in fulfilling a government procurement contract.
-
CAT opens new fronts in Doosan dispute with USITC, District of Delaware complaints
The latest filings come in response to Doosan Bobcat’s previous infringement actions in the U.S. and Europe.
-
Federal Circuit says owners of patents subject to exclusive license still have standing to sue where terms don’t render rights “illusory”
A.L.M. and Ergon granted wide-ranging rights to an exclusive licensee – but retained the right to sue third-party infringers.
-
Nvidia, Western Digital among defendants as vertical chip designer MonolithIC 3D expands multi-district litigation campaign
After filing several U.S. infringement suits in recent months, MonolithIC 3D has just fired off another salvo involving a new set of semiconductor design patents.
-
10x settles with Curio, immediately goes on to sue Element Biosciences over next-generation sequencing patents
In the next-generation sequencing space, 10x Genomics has settled its litigation with Curio Biosciences, just before filing a new patent infringement lawsuit against Element Biosciences in Delaware.
-
FedEx can fight another day in Qualcomm dispute, as Federal Circuit considers IPR real-parties-in-interest
The USPTO withdrew its initial defense of the PTAB’s refusal of FedEx’s arguments around real parties in interest.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.
-
CureVac sues Moderna in Delaware over Spikevax patents, seeking treble damages but no injunction
CureVac sues Moderna for treble damages but not an injunction over 10 patents related to Spikevax. The case adds to broader post-COVID mRNA patent battles.
-
PTAB invalidates Trina Solarâs TOPCon patents, ending parallel U.S. proceedings against Canadian Solar
The PTAB invalidated all claims of two TOPCon patents asserted by Trina Solar against Canadian Solar. The rulings effectively halt the parallel U.S. proceedings, leaving appeal as the only path forward.